Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 4/20 | 0.45 |
| ▸ | CA2 | P00918 | 4/20 | 0.45 |
| ▸ | CA12 | O43570 | 3/20 | 0.45 |
| ▸ | CA7 | P43166 | 3/20 | 0.45 |
| ▸ | CA9 | Q16790 | 3/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | XDH | P47989 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14850502 | 0.82 | MAPK1 (0.57) | MAPK1KDM4EL3MBTL1ATMTDP1 | |
| SCHEMBL14782142 | 0.82 | MAPK1 (0.57) | MAPK1KDM4EL3MBTL1ATMTDP1 | |
| SCHEMBL15994611 | 0.81 | TDP1 (0.55) | MAPK1KDM4EL3MBTL1TDP1ALDH1A1 | |
| SCHEMBL26145810 | 0.80 | MAPK1 (0.37) | MAPK1KDM4EL3MBTL1ATMTDP1 | |
| SCHEMBL4274472 | 0.80 | MAPK1 (0.37) | MAPK1KDM4EL3MBTL1ATMALDH1A1 | |
| SCHEMBL23031061 | 0.80 | MAPK1 (0.55) | MAPK1KDM4EL3MBTL1ATMTDP1 | |
| SCHEMBL4038270 | 0.80 | MAPK1 (0.55) | MAPK1KDM4EL3MBTL1ATMTDP1 | |
| SCHEMBL63531 | 0.80 | MAPK1 (0.55) | MAPK1KDM4EL3MBTL1ATMTDP1 | |
| SCHEMBL18547783 | 0.80 | MAPK1 (0.55) | MAPK1KDM4EL3MBTL1ATMTDP1 | |
| SCHEMBL27282195 | 0.80 | MAPK1 (0.55) | MAPK1KDM4EL3MBTL1ATMTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102395-A1 | INHIBITING HISTONE DEACETYLASE 6 | EIKONIZO THERAPEUTICS, INC. (US) | 2026-04-16 | — | — | US | disclosed |
| EP-4680602-A1 | HETEROCYCLIC COMPOUNDS AS SELECTIVE HDAC6 INHIBITORS | Miralinc Pharma, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| CN-119212707-A | Oxadiazole HDAC6 inhibitors and uses thereof | 艾科尼佐治疗股份有限公司 | 2024-12-27 | — | — | CN | disclosed |
| WO-2024192237-A1 | HETEROCYCLIC COMPOUNDS AS SELECTIVE HDAC6 INHIBITORS | MIRALINC PHARMA, INC. (US) | 2024-09-19 | — | — | WO | disclosed |
| US-20230322747-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322747-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| WO-2023196601-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| US-20230219954-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ASANA BIOSCIENCES, LLC | 2023-07-13 | — | — | US | disclosed |
| US-20230219954-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ASANA BIOSCIENCES, LLC | 2023-07-13 | — | — | US | disclosed |
| US-20230219954-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ASANA BIOSCIENCES, LLC | 2023-07-13 | — | — | US | disclosed |
| US-20110144116-A1 | DERIVATIVES OF (BRIDGED PIPERAZINYL)-1-ALKANONE AND USE THEREOF AS p75 INHIBITORS | SANOFI-AVENTIS (FR) | 2011-06-16 | — | — | US | disclosed |
| US-20090181966-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-07-16 | — | — | US | disclosed |
| US-7504508-B2 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| WO-2008121670-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI-AVENTIS (FR) | 2008-10-09 | — | — | WO | disclosed |
| CN-101018770-A | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARM INC (US) | 2007-08-15 | — | — | CN | disclosed |
| US-20070049603-A1 | Raf inhibitor compounds and methods of use thereof | ARRAY BIOPHARMA INC. | 2007-03-01 | — | — | US | disclosed |
| US-7169325-B2 | Liquid crystalline compound, liquid crystalline composition and retardation film | FUJI PHOTO FILM CO., LTD. (JP) | 2007-01-30 | — | — | US | disclosed |
| EP-1740547-A1 | PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-01-10 | — | — | EP | disclosed |
| US-20050256158-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. | 2005-11-17 | — | — | US | disclosed |
| WO-2005100321-A1 | PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322747-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | HDAC6, HDAC1, HDAC11 | MAPK1 2989/4885KDM4E 2674/4885L3MBTL1 2746/4885 |
| US-20070049603-A1 | Raf inhibitor compounds and methods of use thereof | BRAF, RAF1, ARAF | MAPK1 35/4885KDM4E 3956/4885L3MBTL1 1361/4885 |
| US-20110144116-A1 | DERIVATIVES OF (BRIDGED PIPERAZINYL)-1-ALKANONE AND USE THEREOF AS p75 INHIBITORS | NGF, NTRK2, NTRK3 | MAPK1 981/4885KDM4E 1245/4885L3MBTL1 2968/4885 |
| US-20230219954-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | P2RX3, P2RX2, P2RX1 | MAPK1 3399/4885KDM4E 1683/4885L3MBTL1 3916/4885 |
| US-20050256158-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGDR2, LTB4R2, CYSLTR2 | MAPK1 1369/4885KDM4E 4797/4885L3MBTL1 4677/4885 |
| US-20260102395-A1 | INHIBITING HISTONE DEACETYLASE 6 | HDAC6, HDAC1, HDAC8 | MAPK1 2091/4885KDM4E 866/4885L3MBTL1 570/4885 |
| US-20090181966-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGDR2, LTB4R2, CYSLTR2 | MAPK1 1369/4885KDM4E 4797/4885L3MBTL1 4677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.